Articles tagged with Cell Therapies
Dr. S. Thomas Carmichael, a UCLA neuroscientist, received the 2018 Bernard Sanberg Memorial Award for Brain Repair from ASNTR for his career-long work in stroke recovery mechanisms. His research has shown that the adult brain can form new connections after stroke and may be critical for plasticity in the recovering brain.
Researchers have developed a new way to introduce molecules and therapeutic genes into human cells using ultrafast compression, which can improve cell transfection efficiency. The technique involves compressing cells in microfluidic devices, causing them to take up surrounding fluid and macromolecules.
A novel process produces cell-sized lipid vesicles that can be functionalized to interact with cells, inducing specific cellular responses. The technology has high therapeutic potential for treating Type 2 diabetes.
Researchers have discovered how CAR-T cell therapy kills cancer cells, revealing a key mechanism that can inform the design of safer and more efficient treatments. The study could pave the way for the adaptation of CAR-T therapy to treat solid cancers, including notoriously hard-to-treat brain tumors.
PanTHERA CryoSolutions has discovered a small molecule inhibitor that prevents ice recrystallization, a process causing cell death and damage when freezing cells and tissues. This technology results in faster engraftment and increased incidence of engraftment for clinical settings.
Scientists at Newcastle University have developed a coating that allows individual stromal cells to detach from the surface, enabling continuous cell growth. This innovation can produce up to a billion cells per week, making it ideal for cell-based therapies requiring large numbers of cells.
A new chemical compound has been found to significantly improve the survival of cells during transplantation, a process used in cell-based therapies for various conditions. The antioxidant, Proxison, was tested on lab-grown cells and shown to be 10 times more effective than natural antioxidants in protecting cells from damage.
Researchers identified a 'killer peptide' released by therapy-sensitive cancer cells, which can kill therapy-resistant cells and inhibit metastasis. The peptide enters only cancer cells, preserving healthy tissue.
A new trial combining ibrutinib with personalized cellular therapy CTL119 achieved complete remission in nine out of ten high-risk CLL patients. The treatment showed limited toxicity and improved disease outcomes compared to existing therapies.
A new cell separator developed by University of Surrey Biomedical Engineers uses dielectrophoresis to sort cells electrostatically, reducing costs and increasing efficiency. This innovation has significant promise for stem-cell therapy and cancer research, offering a more affordable and effective solution.
A new study identifies Gamma Delta T cells as adaptable immune cells with immunological memory against previous infections and cancerous targets. This finding challenges traditional views of these cells as 'natural born killers' and presents opportunities for developing new cell therapies and vaccines.
Researchers at CNIC discovered that miR-28 regulates the terminal differentiation of B lymphocytes, blocking the growth of B cell lymphomas. This finding highlights the potential of synthetic miR-28 analogs to inhibit tumor growth in Burkitt lymphoma and diffuse large cell lymphoma.
A new therapeutic agent, ST266, has been shown to prevent loss of cells in the optic nerve and reduce inflammation in a mouse model of multiple sclerosis. Early treatment with ST266 improved visual function and prevented damage to the optic nerve.
Researchers characterized dendritic cells across different human organs, revealing constant surface profiles and tissue-specific signals. The study sheds light on the development of new immune therapies and cancer treatments.
A team of scientists from Helmholtz Zentrum München has isolated and characterized therapy-resistant leukemia cells, which are responsible for relapse in the disease. These cells can be eliminated using modern genetic engineering techniques, offering a new approach to prevent disease relapse.
The study found that surgery performed within 6-9 weeks after neoadjuvant chemoradiation therapy (NCRT) correlates with increased risk of poor outcomes, including perioperative mortality and overall survival. In contrast, an optimal interval of less than 8 weeks is recommended to minimize risks associated with radiation pneumonitis.
In a phase 1 clinical study of 32 participants with advanced B cell non-Hodgkin lymphoma, immunotherapy with defined subsets of T cells showed strong antitumor activity. The therapy was found to be more effective when combined with specific ratios of CD4 and CD8 CAR-T cells and pretreatment chemotherapy regimen.
A new cell therapy product called DUOC-01 promotes faster axon remyelination in mice treated with a demyelinating chemical agent. The treatment also enhances the differentiation of oligodendrocyte progenitor cells, suggesting potential for neuronal repair and remyelination in patients with demyelinating diseases.
A new approach using metabolic imaging could help determine a patient's response to targeted therapies much earlier and with greater precision than traditional tumor shrinkage. This method recognizes a drug's ability to stop cancer cells' energy overuse, allowing for more accurate assessments of treatment success.
A new study has found a way to starve tumors of their blood supply by inhibiting the replenishment of an intracellular substrate needed for vascular endothelial cells to respond to pro-angiogenic signals. This approach limits the growth of new blood vessels and enhances the effectiveness of therapy.
Researchers develop new method to generate large pool of gene-corrected cells, which can repopulate in vivo and treat various disorders
Researchers developed a dual nanoparticle delivery system for piperlongumine and TRAIL, demonstrating increased therapeutic efficacy in vitro and in vivo. The system sensitizes cancer cells to TRAIL, leading to higher apoptotic rates and improved anti-cancer effects.
Researchers at KARBio LLC and Genentech Inc. discovered that targeting human CRTh2 (hCRTh2) depletes immune cells implicated in asthma-associated inflammation, reducing cytokine production and lung inflammation in asthmatic mice. The study's findings support further exploration of hCRTh2 as a therapeutic target for asthma treatment.
Autologous cardiac cells, particularly atrial appendage-derived cells, show promise for gene and RNA therapies in heart failure. The review discusses financial and authority-based restrictions influencing research in this field, highlighting the potential of autologous tissues as cell therapy sources.
Researchers at VIB-UGent demonstrate that adult circulating monocytes can differentiate into macrophages with identical tissue-specific functions and self-maintenance capacities as those from embryonic origin. This discovery paves the way for monocyte-based cellular therapy in diseases associated with macrophage dysfunction, such as pu...
Researchers found that dozens of targeted therapies inhibit T cell activity, which can help fight tumors. However, pairing these drugs with an IL-15 superagonist stimulates T cell activity, preserving cancer-blocking effects. The study suggests a potential way to overcome immunosuppressive effects while maintaining anti-cancer benefits.
Recent advances in T cell therapy have brought the idea of fighting chronic infections and cancers closer to reality. The use of potent cells with a safety mechanism has been demonstrated, and clinical trials have yielded highly promising results.
A recent study by McGill University researchers has made significant progress in understanding the mechanisms responsible for multiple sclerosis and identifying potential new treatments. By targeting a subset of B cells known as GM-CSF-producing B cells, the therapy shows promise in reducing disease activity.
Researchers at Griffith University have developed a new technique for growing cells in three dimensions, allowing them to freely associate and form natural structures. This method, using floating liquid marbles, has the potential to increase cell growth and function, particularly useful for spinal cord transplantation repair.
Kazan researchers compared direct gene and blood cell-mediated therapy for spinal cord injuries, revealing similar recovery outcomes in rats. The study found that both therapies preserved myelinated fibers, with cell-based therapy extending therapeutic influence over longer distances.
A clinical trial of a personalized cell therapy, CTL019, achieved an overall response rate of 57% and complete remissions in eight out of 14 patients with chronic lymphocytic leukemia (CLL). The therapy, developed by Penn researchers, involves reprogramming patients' own T cells to hunt and kill cancer cells.
Natural killer cells are impaired in the tumor microenvironment, but can be restored in normal conditions. Researchers identified two key factors blocking NK cell function: inflammatory cytokine IL-10 and down-regulated NKG2D ligands.
Researchers have successfully used autologous fat cell transplants to improve symptoms of osteoarthritis in patients. The treatment showed significant improvements in pain management and joint mobility, with most patients experiencing a minimum of 50% score improvement after 12 months.
A clinical trial found that patients who received more CD34+ bone marrow cells experienced significant benefits, with improved ejection fraction and lower rates of major adverse cardiac events. The study, which enrolled 161 patients, showed a dose-dependent trend in the effects of cell therapy on heart function.
Rapid lowering of body temperature after a heart attack can minimize damage to the heart muscle. New research highlights the need for faster and more effective cooling techniques to realize the full potential of therapeutic hypothermia.
A new technology developed by VIB/UGent scientists has simplified the production of biotech medicines by truncating complex sugar structures, retaining therapeutic efficiency. This innovation has the potential to make biotech medicine production cheaper and more efficient.
Researchers discovered that nimotuzumab promotes autophagic cell death, enhancing the antitumor effects of chemotherapy and radiation in ESCC cells with high EGFR expression. This finding suggests a potential strategy for improving therapeutic efficacy in esophageal squamous cell carcinoma.
Researchers discovered how Fragile X mental retardation protein affects brain cell protein production, leading to the development of potential therapies for the genetic disorder. The study identified a critical binding site on the ribosome that could be targeted by drugs.
Scientists have discovered a molecule that can induce cell death (apoptosis) in dendritic cells, a key type of immune cell. This understanding may lead to new therapies that shut down dendritic cell activity and reduce an immune reaction.
Researchers found therapeutic hypothermia to be beneficial for some patients following cardiac arrest, but ineffective or even worsening outcomes in others. The study suggests a need for more rigid guidelines to ensure appropriate application of cooling strategies.
New research reveals that macrophage populations mediate tumor cell removal following monoclonal antibody treatment. Additionally, targeting the p57Kip2 pathway in adults with type 2 diabetes may improve β cell function and expand β cell mass.
A new therapy for preventing production of sphingolipids in lymphoma cells has been developed, selectively killing virus-infected cells. The treatment, ABC294640, shows promise in treating primary effusion lymphoma, an aggressive variant of diffuse large B-cell lymphoma caused by viruses.
The university's premier biomedical instrument is expected to provide breakthroughs in treating animal and human health conditions, including cancer. The instrument uses thermal cell therapy and high-resolution imaging to target specific cells and tumors.
Researchers found that mild hypothermia improved behavioral scores and increased surviving neurons in rats with TBI. The treatment also reduced harmful protein levels linked to brain injury and cognitive dysfunction.
Researchers develop a therapeutic strategy that manipulates cellular heterogeneity to treat advanced melanoma. The approach uses a new drug-like molecule in combination with an existing chemotherapy, targeting only melanoma cells and suppressing tumor growth and metastasis.
Researchers have identified two key compounds produced by mast cells that promote fibrogenesis, leading to pulmonary fibrosis. Introducing mast cells into mice lungs can reverse disease protection and cause pulmonary fibrosis.
Researchers at VIB developed a mouse model to study the molecular mechanisms determining cellular identity, enabling targeted manipulation of iPS cells for safer and more effective therapies. This breakthrough advances cell therapy using iPS cells for regenerative medicine applications.
Research demonstrates that immune system's natural killer cells can kill off virus-infected tumor cells, rendering glioblastoma virotherapy less effective. The study suggests temporarily suppressing the immune system may counteract this response and enhance therapy.
Researchers from Ruhr-University Bochum report that impaired protein degradation causes muscle diseases, including filaminopathies. The study found that protection mechanisms against abnormal protein deposits do not work properly in patients, opening up new avenues for therapies.
The new guidelines recommend that all adults with HIV infection be treated, with no CD4 cell count threshold for initiating therapy. Initial regimens include a combination of nucleoside reverse transcriptase inhibitors and nonnucleoside reverse transcriptase inhibitors.
Researchers found that T-bet and RORα proteins enforce specific classes of memory B cells, which can produce antibodies against various infections. This discovery opens the way for developing vaccines that induce long-term immunity towards desired antibody classes.
A study published in JAMA found that using bone marrow cells to treat chronic ischemic heart failure did not show significant improvements in most measures of heart function. However, exploratory analysis revealed a significant effect on left ventricular ejection fraction (LVEF) among patients under 62 years old.
Researchers found that rituximab, a monoclonal antibody, was safe and effective in reducing liver damage in PBC patients who had an incomplete response to UDCA therapy. The study showed significant reductions in alkaline phosphatase levels and anti-mitochondrial antibodies after treatment.
Researchers studied the role of immune responses in oncolytic adenovirus therapy and found that CD8+ T cells mediate antitumor efficacy. The study proposes a new therapeutic regime combining oncolytic adenovirus with immunotherapy.
Researchers at UCLA have identified dihydromyricetin as a potential treatment for acute alcohol intoxication and withdrawal symptoms. The compound blocks the action of alcohol on the brain's GABAA receptors, reducing voluntary consumption without major side effects.
A study of over 26,000 patients found that therapeutic hypothermia was used in only 0.35% of out-of-hospital cardiac arrest cases in the US. Despite its proven benefits in reducing mortality and improving neurologic outcomes after a heart attack, hypothermic therapy is not being widely adopted in clinical practice.
Researchers at the Weizmann Institute have developed a new form of adoptive cell transfer that overcomes limitations of current therapies. This approach uses a donor pool of immune T cells prepared in advance, which are outfitted with receptors to specifically target and destroy tumors.
Researchers have identified a distinct population of immune cells that contribute to the pathogenesis of type 1 diabetes by helping CD8+ T cells elicit autoimmune responses in the pancreas. This subset of CD4+ T cells produces IL-21 and express CCR9, playing a critical role in autoimmune disease.
University of Cincinnati researchers have successfully produced large RNA nanoparticles using a bipartite approach, overcoming challenges in industry-scale production. The nanoparticles, containing small interfering RNA, show a half-life of between five and 10 hours in animal models, are non-toxic and produce no immune response.
Researchers have developed a cell therapy that selectively dampens vascular inflammation induced by LDL, showing substantial protective effects against atherosclerosis. The treatment has been shown to reduce the disease process by up to 70 percent in mouse studies.